Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 6;14:17562864211048336. doi: 10.1177/17562864211048336

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2021

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 1. — Prescription prevalence of single drugs in pediatric MS patients compared with the controls (2018). This figure shows the prescription prevalence of active substances in 613 pediatric PwMS (bars: blue—MS, orange—controls) and the mean numbers of prescriptions per patient with a respective prescription (bars: blue—MS, orange—controls) compared with the matched controls (n = 6130). The active substances ibuprofen (28.4%), cholecalciferol (23.0%), and interferon beta-1a (21.5%) were prescribed most frequently among the pediatric PwMS. Furthermore, these drugs were taken significantly more often by PwMS than the control patients (FDR: q < 0.001). The largest average prescription numbers per MS patient resulted in natalizumab (6.6) and interferon beta-1a (4.6). FDR: false discovery rate; MS: multiple sclerosis; q: p value adjustment according to FDR; PwMS: patients with multiple sclerosis.